The Fly

Bust of smuggling ring likely to beheadwind for LabCorp, says Wells Fargo

Wells Fargo analyst Timothy Daley tells investors in a research note that two weeks ago, a major supplier of research models to the U.S. was arrested for illegal smuggling of non-human primates, a critical part of the biologic R&D pipeline. This development is likely to be a headwind to pre-clinical CROs/Biopharma sponsors sourcing directly, or indirectly, from this supplier for re-sale or use in biologic drug studies like LabCorp (LH), but could potentially benefit pre-clinical CROs not exposed with secure sources of supply due to share gains and incremental pricing power, like Charles River (CRL). The analyst lowered the firm’s forecast for LabCorp’s pre-clincal CRO growth in FY23 by -24%, resulting in the firm’s FY23 EPS estimate falling from $17.73 to $17.47.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on LH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More